In the name of god First Trimester Screening Dr.M.Moradi.

Slides:



Advertisements
Similar presentations
Screening “the systematic application of a test procedure to identify individuals at sufficient risk to warrant diagnostic investigations” CVS 12wks Amniocentesis.
Advertisements

Antenatal Screening Mehreen Yousaf GP STS.
Genetic Testing in Pregnancy
Second-trimester maternal serum screening
Computational Intelligence
Genetic screening.
Genetics and Primary Care
Prenatal Testing for Down Syndrome: Where Do We Stand Today? David B. Fox, MD Riverside Methodist Hospital.
Prenatal Genetics OG Supplemental Information Drs. Deborah Driscoll and Michael Mennuti.
Antenatal Care DR. Yasir Katib MBBS, FRCSC Perinatologest.
GP Shared Care Maternal screening for adverse pregnancy outcome 14th March 2015 Dr Rosalie Grivell Consultant Obstetrician and Maternal Fetal Medicine.
NON – INVASIVE PRENATAL TESTING
Prenatal diagnosis Dr Neda Bogari.
Enhanced Prenatal Screening Program
Biochemical tests and ‘marker chemicals’
IN THE NAME OF GOD. CRITICALLY APPRAISED TOPIC If there is a Non-invasive prenatal testing for aneuploidies with low FPR at first trimester? If we can.
By : Drs Barati Drs Mohammadjafari Drs Masihi Drs aadati Drs Shahbazian DRS Zamanpoor(resident)
Pregnancy & Newborn Screening Developments
Ultrasound markers of chromosomal abnormalities
Limitations of Prenatal Screening and Invasive Procedures In ART Pregnancies Prof.Dr. Mehmet Zeki TANER Gazi University Department of Obstetrics and Gynecology.
TEMPLATE DESIGN © Retrospective Analysis of Amniocentesis in UKMMC ZulidaR, MAJamil Universiti Putra Malaysia, UPM Serdang,
Changes in Chromosome Number
First Trimester Screening
Routine Anomaly Scan Ilse Erasmus.
Amirkabir imaging center dr.m.ali mohammadi 2011.
Objectives Goals of the week scanGoals of the week scan Fetal nuchal translucency in the detection of aneuploidyFetal nuchal translucency in.
Ultrasound in obstetrics III By Dr. Khattab KAEO Assis. Prof. of Obstetrics and Gynaecology Faculty of Medicine, Al-Azhar University, Damietta.
First and Early Second Trimester Diagnosis of Fetal Heart Disease 성균관의대 소아과 삼성제일병원 진단방사선과 민 지 연.
Early Prenatal Screening in Primary Care BC College of Family Physicians 21 st Annual Scientific Assembly Ken Seethram, MD, FRCSC, FACOG Pacific Centre.
National Women’s Screening for Aneuploidy Dr Emma Parry CMFM Clinical Director Maternal-Fetal Medicine National Women’s Health.
Prenatal Diagnosis of Congenital Malformations for Undergraduates
History ♀ ♂ First identified as a cytogenetic syndrome in 1960.
Epidemiological Monitoring and Quality Control of Nuchal Translucency Jack Canick Intensive Course on Screening for Down’s Syndrome Wolfson Institute of.
VI. Hrvatski kongres o ginekološkoj endokrinologiji, humanoj reprodukciji i menopavzi s međunarodnim sudjelovanjem , Brijuni DARIJA STRAH.
In the name of god.
Vajiheh Marsoosi, M.D Associate Professor of TUMS Shariati Hospital.
The Role of Prenatal screening as part of Routine Obstetric Care
Intro Until recently, couples had to choose between taking the risk or considering other options Over the past three decades, prenatal diagnosis-the ability.
NHS Fetal Anomaly Screening Programme Marie Coughlin Screening Lead January 25 th 2010.
Conceptual & technical advances in Down’s syndrome screening Howard Cuckle
Screening for Down’s syndrome
Prenatal Diagnosis affecting Pregnancy Decisions Sarah Jones Research in Allied Health.
Erika Castro, PGY 3 Cook County-Loyola-Provident Family Medicine Residency 2/27/2014 PRENATAL SCREENING AND DIAGNOSIS COUNSELING
Definition & Risk Factors of FGR FGR, also called IUGR is the term used to describe a fetus that has not reached its growth potential because of genetic.
Genetic Testing in Pregnancy Lisbeth M. Lazaron, MD March 2013.
Fetal Diagnosis & Counseling of Pregnancy Options.
UOG Journal Club: January 2016 Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results.
UOG Journal Club: March 2016 Prediction of large-for-gestational-age neonates: screening by maternal factors and biomarkers in the three trimesters of.
UOG Journal Club: July 2013 Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies M. M. Gil, M. S. Quezada, B. Bregant,
Challenges of screening for fetal abnormalities
UOG Journal Club: January 2016
Intro Until recently, couples had to choose between taking the risk or considering other options Over the past three decades, prenatal diagnosis-the.
UOG Journal Club: March 2016
Antenatal Screening Rebecca Sykes.
Ziya Kalem,MD Gurgan Clinic IVF and Women Health Center
UOG Journal Club: May 2017 Increased nuchal translucency thickness and risk of neurodevelopmental disorders S.G. Hellmuth, L.H. Pedersen, C.B. Miltoft,
UOG Journal Club: May 2017 Increased nuchal translucency thickness and risk of neurodevelopmental disorders S.G. Hellmuth, L.H. Pedersen, C.B. Miltoft,
Aneuploidy and NTD screening
DO NOT ORDER at any gestational age.
Jeffrey A. Kuller, MD; Sean C. Blackwell, MD
غربالگری ناهنجاریهای جنین
مدلسازی میزان بروز سندرم داون
Objectives Goals of the week scan
Prenatal Screening for Genetic Conditions
guidance on antenatal screening
Ultrasound in fetal screening ( Down syndrome,…)
NON – INVASIVE PRENATAL TESTING
IN THE NAME OF GOD First trimester screening for aneuploidy
Nuchal translucency screening uses ultrasound to screen for Down syndrome, other conditions caused by an extra chromosome (trisomy 13 and 18), and congenital.
Presentation transcript:

In the name of god First Trimester Screening Dr.M.Moradi

First Trimester Screening A method to identify women at risk for having an aneuploid fetus from the general population Also can identify other birth defects such as congenital heart defects and diaphragmatic hernia Performed during weeks gestation Patient Preferences and earlier diagnosis/ reassurance

All patients have a 2% to 3% risk of birth defects, regardless of their prior history, family history, maternal age, or lifestyle. Chromosome abnormalities account for approximately 10% of birth defects.

A detailed fetal anatomic survey performed at 18 to 22 weeks remains the primary means for detecting the majority of serious ‘‘structural’’ birth defects. first-trimester screening at 11 to 14 weeks has developed into the initial screening test for many patients.

The primary advantage of first trimester screening is earlier diagnosis of abnormalities (or early reassurance of the anxious patient), with the option of an earlier and safer pregnancy termination.

Advantages of 1st Trimester Screening Information earlier, more options Reduce number of invasive procedures May identify other severe anomalies (or risk for) at time of scan and increased risk of adverse pregnancy outcome—referral for 2 nd Δ evals. Good time to date pregnancy accurately NT good for multiple gestation

First Trimester Screening GOALS of this screen: To increase sensitivity, decrease false-positive rates To decrease number of “unnecessary” invasive prenatal diagnosis tests. NOT to increase number of elective abortions. U/S measurements (NT) and free B-hCG, PAPP-A

Use of the guidelines proposed by the Fetal Medicine Foundation have resulted in a high consistency in results

Nuchal translusency

History ◦ Dr.langdon Down 1866 ◦ 1980s ◦ 1992…..prof Nicolaid…. Normal range? Mechanism? Normal Karyotype with increased NT

The mechanism for increased NT may vary with the underlying condition. The most likely causes include heart strain or failure and abnormalities of lymphatic drainage. Evidence for heart strain includes the finding of increased levels of atrial and brain natriuretic peptide mRNA in fetal hearts among trisomic fetuses

Nuchal Translucency Measurements must be performed by certified individual!

True sagital Position Caliper Separation of amnion magnification

The normal range for NT measurements is gestational age dependent. the median NT increases from 1.3 mm at a crown-rump length (CRL) of 38 mm to 1.9 mm at a CRL of 84 mm. The 95th percentile increases from 2.2 mm at a crown rump length of 38 mm to 2.8 mm at a CRL of 84 mm.

The ability to measure NT and obtain reproduciblen results improves with training; good results are achieved after 80 and 100 scans for the transabdominal and the transvaginal routes, respectively

screening Basic ◦ NT ◦ BIOCHEMISTRY Advanced

The two most effective maternal serum markers currently used in the first trimester are pregnancy- associated plasma protein A (PAPPA) and free B-human chorionic gonadotrophin (B-hCG). Maternal serum free b-human chorionic gonadotropin (b-hCG) normally decreases with gestation after 10 weeks and maternal serum PAPP-A levels normally increase. Levels of these two proteins tend to be increased and decreased, respectively, in pregnancies affected by trisomy 21.

PAPP-A and Free B- hCG On average, baby with trisomy 21 will have 2.0 Mom for B-hCG and 0.4 MoM PAPP-A

Basic screening High risk 1/50 Moderate risk Low risk 1/1ooo

Advanced ◦ Nasal bone ◦ Facial angle ◦ Ductus venosus ◦ Tricuspid regurgitation

Professor Kypros Nicolaides.

The fetal nasal bone can be visualized by sonography at 11–13+6 weeks of gestation (Cicero et al 2001). Several studies have demonstrated a high association between absent nasal bone at 11–13+6 weeks and trisomy 21, as well as other chromosomal abnormalities.

Three line

Fronto maxillary angle

GA dependent CRL=45mm, 84’ CRL=84mm, 76’ Above 95% for age=increased risk of trisomy

Ductus venosus

Sample size Angle Filter sweep speed

Tricuspid regurgitation

Fetal heart rate In normal pregnancy, the fetal heart rate (FHR) increases from about 100 bpm at 5 weeks of gestation to 170 bpm at 10 weeks and then decreases to 155 bpm by 14 weeks. At 10–13+6 weeks, trisomy 13 and Turner syndrome are associated with tachycardia, whereas in trisomy 18 and triploidy there is fetal bradycardia (Figure 5; Liao et al 2001). In trisomy 21, there is a mild increase in FHR.

Urinary bladder

In first trimester ◦ >7mm=megacystitis ◦ 7-15 mm….. ◦ >15mm……